DoubleTwist Licenses CAT to Rigel Pharmaceuticals | GenomeWeb

NEW YORK, April 17 - Rigel Pharmaceuticals has agreed to license DoubleTwists's Clustering and Alignment Tools (CAT) for organizing expressed sequence tags and mRNA sequences into full-length gene sequences, the companies said Tuesday.

Rigel, based in South San Francisco, will use the tools in bioinformatics analysis of potential drug targets. The company focuses on identifying molecules that regulate a cell's response to disease, and has targeted asthma/allergy, autoimmune, cancer, and other diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.